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Abstract The porphyrias comprise a heterogeneous group
of rare, primarily hereditary, metabolic diseases caused by a
partial deficiency in one of the eight enzymes involved in
the heme biosynthesis. Our aim was to assess whether acute
or cutaneous porphyria has been associated with excess
risks of adverse pregnancy outcomes. A population-based
cohort study was designed by record linkage between the
Norwegian Porphyria Register, covering 70% of all known
porphyria patients in Norway, and the Medical Birth
Registry of Norway, based on all births in Norway during
1967–2006. The risks of the adverse pregnancy outcomes
preeclampsia, delivery by caesarean section, low birth
weight, premature delivery, small for gestational age
(SGA), perinatal death, and congenital malformations were
compared between porphyric mothers and the rest of the
population. The 200 mothers with porphyria had 398
singletons during the study period, whereas the 1,100,391
mothers without porphyria had 2,275,317 singletons. First-
time mothers with active acute porphyria had an excess risk
of perinatal death [adjusted odds ratio (OR) 4.9, 95%
confidence interval (CI) 1.5–16.0], as did mothers with the
hereditable form of porphyria cutanea tarda (PCT) (3.0,
1.2–7.7). Sporadic PCT was associated with an excess risk
of SGA [adjusted relative risk (RR) 2.0, 1.2–3.4], and for
first-time mothers, low birth weight (adjusted OR 3.4, 1.2–
10.0) and premature delivery (3.5, 1.2–10.5) in addition.
The findings suggest women with porphyria should be
monitored closely during pregnancy.
Abbreviations
ALA delta aminolevulinic acid
ALAD delta aminolevulinic acid dehydratase
AIP acute intermittent porphyria
CEP congenital erythropoietic porphyria
PBG porphobilinogen
PCT porphyria cutanea tarda
EPP erythropoietic protoporphyria
HCP hereditary coproporphyria
VP variegate porphyria
SGA small for gestational age
NAPOS the Norwegian Porphyria Centre
MBRN the Medical Birth Registry of Norway
OR odds ratio
RR relative risk
BMI body mass index
Introduction
The porphyrias comprise a heterogeneous group of rare,
mainly hereditary, diseases caused by partial deficiencies in
one of the eight enzymes involved in the heme biosynthesis
(Puy et al. 2010). Symptoms of disease can present as acute
attacks of abdominal pain and neuropsychiatric symptoms
[delta aminolevulinic acid dehydratase (ALAD) deficiency
and acute intermittent porphyria (AIP)], cutaneous symp-
toms [congenital erythropoietic porphyria (CEP), porphyria
cutanea tarda (PCT), and erythropoietic protoporphyria
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DOI 10.1007/s10545-010-9231-2(EPP)] or both (hereditary coproporphyria (HCP) and
variegate porphyria (VP)). Acute attacks are triggered by
various factors, such as endocrine changes, physical or
emotional stress, alcohol consumption, smoking, and a
wide array of drugs. Cutaneous symptoms consist of
blistering and fragile skin on sun-exposed areas (CEP,
PCT, HCP, VP) and photosensitization (EPP). With the
exception of PCT, which also occurs in a sporadic,
nonhereditary form, most porphyrias are inherited in an
autosomal dominant fashion with low clinical penetrance.
As with many other rare diseases, little is known about
the porphyrias and reproduction. Pregnancy has been
reported to exacerbate or improve cutaneous symptoms in
women with PCT (Baxi et al. 1983; Loret de Mola et al.
1996; Aziz Ibrahim and Esen 2004) and EPP (Bewley et al.
1998; Jacquemyn 2003; Madu and Whittaker 2006), and
women with AIP sometimes have their first acute attack
during pregnancy (Engelhardt et al. 2004; Cappell 2008).
However, how porphyria can affect pregnancy outcomes
has seldom been investigated, and the body of evidence
only consists of case reports and small case series. Acute
porphyrias have been implied to be risk factors for low
birth weight, growth retardation, premature delivery, spon-
taneous abortion, and perinatal death (Brodie et al. 1977;
Olund 1988; Kanaan et al. 1989; Milo et al. 1989; Wenger
et al. 1998; Aggarwal et al. 2002; Andersson et al. 2003;
Muralidhar et al. 2006; Cappell 2008), whereas PCT has
been suggested to increase the risk of preeclampsia (Loret
de Mola et al. 1996; Aziz Ibrahim and Esen 2004).
The aim of this study was to assess whether cutaneous or
acute porphyria has been associated with excess risks of
adverse pregnancy outcomes, specifically preeclampsia,
delivery by caesarean section, low birth weight, premature
delivery, small for gestational age (SGA) infants, perinatal
death, and congenital malformations. Two national regis-
tries, the Norwegian Porphyria Register and the Medical
Birth Registry of Norway (MBRN), provided the basis of a
large-scale population-based cohort study to address these
issues.
Methods
The Norwegian Porphyria Centre (NAPOS) has a national
responsibility for diagnosing porphyric disease in Norway.
All Norwegian porphyria patients, both with active disease
and those presymptomatically examined (latent porphyria)
are invited to participate in the Norwegian Porphyria
Register, established in 2002 and based on written consent.
Approximately 70% of all known porphyria patients in
Norway participate by filling in a disease-specific ques-
tionnaire at the time of diagnosis and a follow-up
questionnaire every second year thereafter. In addition,
laboratory data of porphyrin analyses are included when-
ever routine samples are sent for analyses. The register
contains information on diagnosis, biochemical character-
istics, symptoms, treatment, daily life activities, and quality
of life. By September 2009, 604 patients were registered:
335 females and 269 males. Established in 1967, the
MBRN is based on compulsory notification of all live
births and stillbirths in the country from 16 weeks of
gestation and from 2001 from 12 weeks of gestation (Irgens
2000). The MBRN comprises demographic data on parents
and child, maternal health before and during index
pregnancy, interventions and complications during preg-
nancy and delivery, and the newborns’ condition. The
MBRN is routinely linked to the Central Population
Registry to obtain data on death dates.
During the autumn of 2009, all women older than
18 years in the Norwegian Porphyria Register were sent a
letter of information about our study. Two women refrained
from participation. Data on diagnosis, biochemical charac-
teristics (highest recorded urinary excretion of ALA and
PBG in women with acute porphyrias (AIP, HCP, or PV),
highest recorded total urine porphyrins in women with
PCT, and highest recorded erythrocyte protoporphyrins in
women with EPP), disease status, and lifestyle parameters
of 318 women with porphyria were obtained. Enabled by
each woman’s unique national identification number, these
data were linked with records of deliveries at the MBRN.
Data on year of delivery, maternal age, parity, preeclampsia,
caesarean section, birth weight, gestational age, perinatal
death (stillbirth at gestational age ≥16 weeks, or death
during the first 7 days of life), and congenital malforma-
tions (any and serious, as defined by the MBRN) were
obtained from the MBRN. SGA, a proxy for in utero
growth retardation, was defined as birth weight below the
tenth percentile for actual gestational age (Skjaerven and
Bakketeig 1989). Multiple pregnancies were excluded. The
study population ultimately consisted of the 2,275,715
singletons born between 1967 and 2006 by 1,100,591
unique mothers. The exposed group consisted of the 398
singletons born by the 200 mothers with porphyria.
Biochemical data standardized by urine creatinine values
were available for 180 of these mothers.
In agreement with others (De Siervi et al. 1999;
Kauppinen and von und zu Fraunberg 2002), the 90 women
with acute porphyria (AIP, HCP, or VP) were categorized as
having active or latent disease depending on whether or not
they had reported symptoms that could be attributed to
acute porphyria to the Norwegian Porphyria Register.
Deliveries by women with active and latent disease were
then analyzed separately. Deliveries by women with PCT
were stratified according to whether a genetic cause of the
disease had been established by demonstration of a
mutation in the uroporphyrinogen decarboxylase gene
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mothers with unknown PCT status were excluded from
further analyses. Because of the small number of deliveries
in the EPP group, they were also excluded from further
analyses. No patients with CEP or ALAD deficiency were
registered in the Norwegian Porphyria Register.
The Mann–Whitney U test was used to compare
biochemical data. Risks of adverse pregnancy outcomes
were compared between the porphyric mothers and the
rest of the population using 2×2 tables and logistic
regression models (STATA Intercooled, version 9). For
rare outcomes, the effect-estimate odds ratio (OR) was
considered a sufficiently good approximation of the
relative risk (RR). For the SGA outcome, however, log
binominal regression models were used to estimate the
RRs directly. Maternal age, parity, and year of delivery
were considered possible confounders and hence adjusted
for as categorical variables in the regression models
(maternal age: <25, 25-34, 35+ years, parity: nulliparous/
multiparous, year of delivery: 1967-1976, 1977-1986,
1987-1996, 1997-2006). Two-sided p values <0.05 were
considered statistically significant. ORs and RRs are
presented with 95% confidence intervals (CI). We checked
for statistically significant interactions between exposure
and each of the possible confounders; none were found.
As subsequent deliveries by the same mother are not
independent incidents, robust variances, CIs and p values
were estimated using the “cluster” function in STATA, and
subanalyses stratified according to parity were also
performed.
Results
The 200 mothers with porphyria had 398 singleton
deliveries between 1967 and 2006 (Table 1). Compared
with controls, they were in general younger, had a higher
parity, and a higher proportion of deliveries during the
earlier parts of the study period.
Women with active acute disease had higher recorded
urinary excretion of ALA (p=0.013) and PBG (p=0.001)
compared with women with latent acute disease (Table 2).
There were no statistically significant differences between
the highest recorded urinary excretions of total porphyrins
among the subgroups with PCT. All women with PCT had
a high urinary excretion of uro- and hepta porphyrins
compared with coproporhyrins.
Among the 136 deliveries in the group with active acute
porphyria, the estimate of excess risk of perinatal death did
not reach statistical significance (Table 3). However, when
the analyses were restricted to firstborn children only, an
almost fivefold increased risk of perinatal death was
observed [adjusted OR 4.9 (1.5-16.0)]. Among the 95
deliveries in the familial PCT group, a threefold increased
risk of perinatal death was observed (Table 4). All the
women experiencing perinatal loss belonged to different
families and carried private mutations (three in the
hydroxymethylbilane synthase gene, one in the protopor-
phyrinogen oxidase gene, and four in the uroporphyrinogen
decarboxylase gene), as is common in the porphyrias.
Among the 68 deliveries in the sporadic PCT group, a
two-fold increased risk of SGA was observed (Table 4).
When analyses were restricted to firstborn children only,
there were also increased risks of low birth weight [adjusted
OR 3.4 (1.2-10.0)] and premature delivery [adjusted OR
3.5 (1.2-10.5)]. No case of preeclampsia was observed
among mothers with sporadic PCT (Table 4). For mothers
with familial PCT, a nonsignificant estimate of a twofold
increased risk of preeclampsia was observed. Restricting
analyses to firstborn children only did not alter this
estimate.
Discussion
First-time mothers with active acute porphyria and mothers
with familial PCT had excess risks of experiencing perinatal
loss. Mothers with sporadic PCT had an excess risk of giving
birth to SGA infants, and first-time mothers with sporadic
PCT also had increased risks of low birth weight infants and
premature delivery. For the remainder, and thus the majority
of the adverse pregnancy outcomes studied, no excess risks
were observed for porphyric mothers.
Pregnancy outcomes in porphyric women have previ-
ously not been examined in large-scale population-based
cohort studies, and the application of this design is the
greatest strength of this study. Reporting to the MBRN is
compulsory, and the degree of completeness is very high
(Irgens 2000). Several variables have been validated and
found to be satisfactory (Baghestan et al. 2007; Kubon et al.
2007), indicating reliable data. One weakness of the study,
however, is the misclassification of an unknown number of
mothers with porphyria as controls. Porphyric mothers not
participating in the Norwegian Porphyria Register, as well
as undiagnosed mothers, were included in the control
group. This was probably particularly relevant for deliveries
in the most recent time periods, during which mothers
might not have been diagnosed by the time of data
collection in 2009, especially mothers with PCT, which
usually occurs after childbearing age. However, as this
misclassification would have been independent of the
outcomes registered, it would have caused effect estimates
to be biased toward the null value. The possibility of
residual confounding is another potential weakness. In
particular, important lifestyle parameters are lacking in the
MBRN. Maternal educational level, a useful proxy of social
J Inherit Metab Dis (2011) 34:217–223 219Table 1 Singleton deliveries by women with porphyria and the rest of the population (controls). Norway, 1967-2006
Acute intermittent
porphyria (AIP)
Hereditary
coproporphyria (HCP)
Variegate
porphyria (VP)
Erythropoietic
protoporphyria (EPP)
Porphyria cutanea
tarda (PCT)
Controls
No. singleton deliveries 175 2 21 15 185 2,275,317
No. mothers 80 1 9 8 102 1,100,391
Characteristics of population
Maternal age in years (%)
<25 36.6 50.0 42.9 6.7 35.1 33.0
25-34 57.7 50.0 47.6 86.7 60.5 57.0
35+ 5.7 0.0 9.5 6.7 4.3 10.0
Parity (%)
Nulliparous 39.4 50.0 33.3 46.7 38.4 41.3
Multiparous 60.6 50.0 66.7 53.3 61.6 58.7
Year of delivery (%)
1967-1976 26.3 0 47.6 26.7 61.1 27.4
1977-1986 28.0 50 38.1 26.7 21.1 22.2
1987-1996 29.1 50 9.5 20.0 10.8 25.6
1997-2006 16.6 0 4.8 26.7 7.0 24.9
No. adverse pregnancy outcomes
Pre-eclampsia/eclampsia 2 0 1 0 5 66,211
Caesarean section 9 0 1 3 10 207,947
Birth weight <2500 g 3 0 2 3 13 95,500
Missing data 5335
Gestational age <37 weeks 9 0 2 2 12 124,959
Missing data 11 13 121,552
Small for gestational age 20 0 2 4 31 232,051
Missing data 11 13 126,028
Perinatal death
a 3 0 1 1 5 29,938
Congenital
malformation, any
2 1 1 0 3 73,106
Congenital
malformation, serious
b
1 0 1 0 3 47,375
aGestational age ≥16 weeks, stillborn or died during first seven days of life
bAs defined by the Medical Birth Registry of Norway
Table 2 Biochemical characteristics of 180 mothers with porphyria
Diagnosis Analyte (unit) Upper reference limit No. Median
(25-75 percentiles)
Latent acute porphyria
a ALA (μmol/mmol creatinine) <5.0 25 4.2 (2.5-7.2)
PBG (μmol/mmol creatinine) <0.8 23 2.1 (0.4-7.9)
Active acute porphyria
a ALA (μmol/mmol creatinine) <5.0 59 6.7 (3.8-11.8)
PBG (μmol/mmol creatinine) <0.8 58 7.2 (3.3-13.9)
Erythropoietic protoporphyria Free erythrocyte protoporphyrin (μmol/L erythrocytes) <1.9 7 19.0 (7.8-34.3)
Sporadic porphyria cutanea tarda Total urine porphyrins (nmol/mmol creatinine) <30 37 1,028 (686-1467)
Familial porphyria cutanea tarda Total urine porphyrins (nmol/mmol creatinine) <30 44 825 (463-1350)
Unknown type porphyria cutanea tarda Total urine porphyrins (nmol/mmol creatinine) <30 8 1,068 (600-2118)
ALA delta aminolevulinic acid, PBG porphobilinogen
aAcute intermittent porphyria, hereditary coproporphyria, or variegate porphyria
220 J Inherit Metab Dis (2011) 34:217–223status, and body mass index (BMI) are not recorded, and
smoking habits were only recorded from 1999 onward.
Patients with acute porphyrias have to adhere to a healthy
lifestyle to avoid inducing acute attacks. PCT, however, is
precipitated by factors such as iron overload, hepatitis,
alcohol use, and estrogens. Thus, lifestyle factors could be
the cause of the association between PCT and adverse
pregnancy outcomes.
In the largest study on porphyrias and pregnancy to date,
the authors reviewed the obstetric histories of 50 women
with active acute porphyria and their total of 129
pregnancies during the 1950s and 1960s (Brodie et al.
1977). They observed an 8% frequency of perinatal death,
whereas in our study, a frequency of 3.2% was found. In
our cohort, this represented an excess risk of perinatal death
compared with the general population. As the study by
Brodie et al. did not include a control group, their results
cannot be directly compared with ours.
Published case reports on four pregnancies by three
women with active AIP reported that all four infants were
Table 3 Risk of selected adverse outcomes in pregnancies of women with latent and active acute porphyria in comparison with the rest of the
population (controls). Norway, 1967-2006
Outcome Controls
(N=2,275,317)
Latent acute porphyria (N=62) Active acute porphyria (N=136)
Per 100 deliveries Per 100
deliveries
OR crude
(95% CI)
OR adjusted
a
(95% CI)
Per 100
deliveries
OR crude
(95% CI)
OR adjusted
a
(95% CI)
Preeclampsia and/or eclampsia 2.9 0.0 - - 2.2 0.8 (0.2-3.3) 0.8 (0.2-3.6)
Caesarean section 9.1 4.8 0.5 (0.2-1.5) 0.5 (0.2-1.6) 5.1 0.5 (0.2-1.5) 0.6 (0.2-1.7)
Birth weight <2,500 g 4.2 1.6 0.4 (0.1-2.7) 0.4 (0.1-2.8) 2.9 0.7 (0.3-1.9) 0.7 (0.3-1.9)
Gestational age <37 weeks 5.8 0.0 - - 8.7 1.6 (0.8-3.0) 1.6 (0.8-3.1)
Small for gestational age
b 10.8 9.8 0.9 (0.4-2.2) 0.9 (0.4-2.2) 12.7 1.2 (0.6-2.2) 1.1 (0.6-2.1)
Perinatal death
c 1.4 0.0 - - 3.2 2.3 (0.9-6.3) 2.3 (0.8-6.1)
Congenital malformation, any 3.2 3.2 1.0 (0.2-4.1) 1.0 (0.3-4.2) 1.5 0.4 (0.1-1.8) 0.5 (0.1-1.9)
Congenital malformation, serious 2.1 3.2 1.6 (0.4-6.4) 1.6 (0.4-6.5) 0.0 - -
OR odds ratio, CI confidence interval
aAdjusted for year of delivery (1967-1976, 1977-1986, 1987-1996, 1997-2006), maternal age (<25, 25-34, 35+ years) and birth order (nulliparous/
multiparous)
bEffect measure relative risk (RR)
cGestational age ≥16 weeks, stillborn or died during first 7 days of life
Table 4 Risk of selected adverse outcomes in pregnancies of women with sporadic and familial porphyria cutanea tarda in comparison with the
rest of the population (controls). Norway, 1967-2006
Outcome Controls
(N=2,275,317)
Sporadic porphyria cutanea tarda (N=68) Familial porphyria cutanea tarda (N=95)
Per 100 deliveries Per 100
deliveries
OR crude
(95% CI)
OR adjusted
a
(95% CI)
Per 100
deliveries
OR crude
(95% CI)
OR adjusted
a
(95% CI)
Preeclampsia and/or eclampsia 2.9 0.0 - - 5.3 1.9 (0.6-6.1) 2.2 (0.7-7.4)
Caesarean section 9.1 2.9 0.3 (0.1-1.2) 0.6 (0.1-2.6) 5.3 0.6 (0.2-1.6) 0.8 (0.3-2.5)
Birth weight <2,500 g 4.2 8.8 2.2 (0.8-5.6) 2.2 (0.8-5.6) 5.3 1.3 (0.5-3.4) 1.3 (0.5-3.5)
Gestational age <37 weeks 5.8 9.7 1.7 (0.8-3.8) 1.8 (0.8-4.1) 5.7 1.0 (0.4-2.6) 1.0 (0.4-2.8)
Small for gestational age
b 10.8 24.2 2.2 (1.3-3.7) 2.0 (1.2-3.4) 13.6 1.3 (0.7-2.4) 1.2 (0.6-2.2)
Perinatal death
c 1.4 1.6 1.1 (0.2-8.1) 0.9 (0.1-6.7) 4.5 3.4 (1.3-8.5) 3.0 (1.2-7.7)
Congenital malformation, any 3.2 1.5 0.4 (0.1-3.1) 0.6 (0.1-4.3) 2.1 0.6 (0.2-2.5) 0.8 (0.2-3.0)
Congenital malformation, serious 2.1 1.5 0.7 (0.1-4.9) 0.9 (0.1-6.8) 2.1 1.0 (0.3-3.9) 1.2 (0.3-4.8)
OR odds ratio, CI confidence interval
aAdjusted for year of delivery (1967-1976, 1977-1986, 1987-1996, 1997-2006), maternal age (<25, 25-34, 35+ years), and birth order (nulliparous/
multiparous)
bEffect measure relative risk (RR)
cGestational age ≥16 weeks, stillborn or died during first seven days of life
J Inherit Metab Dis (2011) 34:217–223 221born SGA and one died shortly after delivery (Olund 1988;
Wenger et al. 1998; Aggarwal et al. 2002). Others
(Muralidhar et al. 2006) reported that of four pregnancies
by a woman with VP, two infants were SGA and two died
perinatally. Brodie et al. reported that babies born after an
acute attack had occurred during pregnancy had lower birth
weight than if no acute attack had occurred, but is not
apparent whether this difference was due to in utero growth
retardation or premature delivery. A publication bias toward
pregnancies with adverse outcomes is to be expected in
case reports. We did not observe an excess risk of SGA for
mothers with active acute porphyria.
A review of six published case reports on PCT and
pregnancy reported that all had “good perinatal outcomes”,
but two developed mild preeclampsia and one gestational
diabetes (Loret de Mola et al. 1996). Based on this report,
others have also suggested an association between PCT and
preeclampsia (Aziz Ibrahim and Esen 2004). We cannot
exclude nor confirm an association. The point estimates of
excess risk suggested a twofold increased risk of pre-
eclampsia in familial PCT, without reaching statistical
significance, and no excess risk in sporadic PCT.
To our knowledge, no one has previously demonstrated an
association between sporadic PCT and SGA infants, and for
first-timemothers,asignificantexcessriskoflowbirthweight
and premature delivery. More than 24% of singletons born by
mothers with sporadic PCT had a weight below the tenth
percentile for their actual gestational age, whereas no such
excess risk was observed in familial PCT. Lifestyle-related
factors such as alcohol use and hepatitis are, to a larger extent,
associatedwithsporadicPCTthanisfamilialPCT(Aarsandet
al. 2009). At the time of diagnosis, 75% of women in the
sporadic PCT group reported smoking daily or occasionally,
whereas 22% in the familial PCT group did the same.
Frequencies of inactive life style (less than 1 h physical
activity per week) were 27% and 13% respectively. Smoking
during pregnancy is a well known risk factor of low birth
weight and SGA (Reeves and Bernstein 2008), and inactive
lifestyle is associated with high BMI, which is a suggested
risk factor of preterm delivery (Torloni et al. 2009).
Therefore, a less healthy lifestyle among women with
sporadic PCT than those with familial PCT might explain
the observed differences in risk of low birth weight, preterm
delivery, and SGA.
The opposite pattern was observed for perinatal death, of
which mothers with familial PCT, but not with sporadic
PCT, had an excess risk. PCT has been associated with
diabetes (Bleasel and Varigos 2000), which is a known risk
factor for perinatal death (Balsells et al. 2009). However,
none of the women with PCT were registered with
pregestational or gestational diabetes in the MBRN,
although complicating factors such as diabetes are, in
general, underreported to some extent (Engeland et al.
2009). A common or coinherited genetic cause of both
familial PCT and perinatal death could be an explanation,
even though the four women with familial PCT and
perinatal loss all belonged to different families and
harbored private mutations in the uroporphyrinogen decar-
boxylase gene.
An increased risk of perinatal death was also observed
for mothers with active acute porphyria but not for mothers
with latent disease. Active, symptomatic disease is charac-
terized by increased plasma and urine levels of heme
precursors during acute attacks, and as many as two thirds
of patients with active AIP have increased levels also when
in remission (Kauppinen and von und zu Fraunberg 2002).
However, though less common, patients with latent disease
can also present with increased urine and plasma levels.
The exact mechanism by which the heme precursors cause
acute symptoms is not fully understood, but neurotoxicity
has been suggested (Pischik and Kauppinen 2009). Whether
the precursors can cross the placental barrier and be harmful
to the fetus, damage the placenta, or in some other way
compromise the intrauterine environment, remains highly
speculative. Alternatively, treatment of porphyric attacks
might be harmful, even if several recently published case
reports have suggested the use of heme arginate during
pregnancy is safe (Marsden and Rees 2010; Badminton and
Deybach 2006). Yet again, a common or coinherited genetic
cause of active acute porphyria and perinatal loss might
exist, even if the women had different mutations as the cause
of their acute porphyria.
In conclusion, in this population-based cohort study,
first-time mothers with active acute porphyria and mothers
with familial PCT had excess risks of perinatal loss.
Mothers with sporadic PCT had excess risks of SGA
infants. The results must be interpreted with care and need
to be confirmed by others. However, the findings suggest
that women with porphyria should be monitored closely
during pregnancy.
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